Fisher & Paykel Healthcare Corporation Limited AI Stock Analysis
Want to see NZ:FPH full AI Analyst Report?
Fisher & Paykel Healthcare Corporation Limited (FPH) AI Stock Analysis
Fisher & Paykel Healthcare Corporation Limited
(NZX:FPH)
The score is driven primarily by strong financial performance (high margins, low leverage, improved cash generation) and supportive technical momentum (price above key moving averages, positive MACD). Offsetting factors are expensive valuation (very high P/E with modest yield) and FY27 execution/macro risks flagged on the earnings call (tariffs, surcharges, FX sensitivity, and potential hardware growth normalization).
Fisher & Paykel Healthcare Corporation Limited (FPH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- NZD 15.88B
- Dividend Yield
- 1.24%
- Average Volume (3M)
- 537.80K
- Price to Earnings (P/E)
- 61.6
- Beta (1Y)
- 1.67
- Revenue Growth
- 15.59%
- EPS Growth
- 23.94%
- Country
- NZ
- Employees
- 7,396
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Fisher & Paykel Healthcare Corporation Limited Business Overview & Revenue Model
Company Description
Operating globally, Fisher & Paykel Healthcare Corporation Limited specializes in the development, manufacturing, and marketing of a wide array of medical device products and systems. These solutions are primarily utilized for acute and chronic respi...
How the Company Makes Money
FPH primarily makes money by selling medical devices and recurring-use consumables used in respiratory support and sleep apnea therapy. A significant portion of revenue is typically driven by ongoing demand for single-patient-use or regularly replace...
Fisher & Paykel Healthcare Corporation Limited Earnings Call Summary
The earnings call conveyed a predominantly positive operational and financial performance: strong top-line growth, substantial NPAT expansion, margin improvement, robust cash flow, higher dividends and continued investment in capacity and R&D. The company provided constructive FY'27 guidance but also clearly articulated material near-term headwinds — notably U.S. tariffs, surcharges from the Middle East conflict, FX/hedging losses, and the risk of hardware growth normalizing after an exceptional year. Management stressed that continuous improvement and manufacturing/network flexibility should offset many of these pressures, but several macro and policy risks remain.
Q4-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided FY27 operating revenue of NZ$2.45–2.57 billion (implying ~6–11% growth, midpoint ≈9%) and net profit after tax of about NZ$500–550 million, built on assumptions including a 10% U.S. tariff on certain New‑Zealand‑made respiratory products for the full year (estimated ~70 basis‑point adverse gross‑margin impact, ~20 bps improvement versus FY26), continued Middle East‑related surcharges of ~45 bps (raw materials) and ~25 bps (freight) (netting to ~50 bps negative to gross margin year‑on‑year after tariff movement) that management expects to more than be offset by continuous‑improvement savings; FY27 capital expenditure is expected at ~NZ$230 million (including ~NZ$125m on land and buildings), operating expenses (R&D and SG&A) are guided to mid‑ to high‑single‑digit growth (R&D was NZ$235.5m, 10% of revenue in FY26), and management highlighted FX and air‑freight as risks (FY26 hedging losses ~$21m pretax; end‑April FY27 hedging loss estimate ~$17m and ~$1m translation loss; ~NZ$2–3m NPAT sensitivity per 1% currency move).
Fisher & Paykel Healthcare Corporation Limited Financial Statement Overview
Summary
Strong overall fundamentals: high and improving profitability (≈64% gross, ≈29% operating, ≈20% net margin), conservative balance sheet with very low leverage, and strengthened cash generation (operating cash flow ≈663M; free cash flow ≈490M). Main constraint on the score is historical variability—profitability and free cash flow were notably weaker/uneven in 2022–2024 before rebounding.
Income Statement
86Very PositiveBalance Sheet
92Very PositiveCash Flow
84Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.34B | 2.34B | 1.87B | 1.61B | 1.48B | 1.52B |
| Gross Profit | 1.50B | 1.50B | 1.18B | 971.56M | 881.22M | 936.67M |
| EBITDA | 816.70M | 825.60M | 611.44M | 347.08M | 410.81M | 566.55M |
| Net Income | 468.50M | 468.50M | 349.03M | 121.57M | 233.18M | 348.36M |
Balance Sheet | ||||||
| Total Assets | 2.85B | 2.85B | 2.36B | 2.28B | 2.20B | 2.11B |
| Cash, Cash Equivalents and Short-Term Investments | 461.10M | 461.10M | 244.74M | 82.00M | 121.00M | 289.90M |
| Total Debt | 146.10M | 146.10M | 141.85M | 189.10M | 145.80M | 104.30M |
| Total Liabilities | 738.20M | 738.20M | 611.07M | 522.60M | 451.10M | 427.30M |
| Stockholders Equity | 2.12B | 2.12B | 1.75B | 1.76B | 1.75B | 1.68B |
Cash Flow | ||||||
| Free Cash Flow | 490.40M | 490.40M | 439.52M | 90.60M | 26.90M | 154.50M |
| Operating Cash Flow | 663.20M | 663.20M | 507.63M | 429.60M | 238.20M | 324.30M |
| Investing Cash Flow | -195.20M | -195.20M | -95.31M | -339.00M | -11.30M | -89.50M |
| Financing Cash Flow | -276.70M | -276.70M | -248.17M | -128.70M | -197.10M | -235.80M |
Fisher & Paykel Healthcare Corporation Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NZ:FPH, the sentiment is Positive. The current price of 49.29 is above the 20-day moving average (MA) of 48.10, above the 50-day MA of 47.06, and above the 200-day MA of 40.85, indicating a bullish trend. The MACD of 0.51 indicates Negative momentum. The RSI at 63.94 is Neutral, neither overbought nor oversold. The STOCH value of 86.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NZ:FPH.
Fisher & Paykel Healthcare Corporation Limited Peers Comparison
Overall Rating
NZ:FPH80Outperform
NZ:EBO60Neutral
NZ:RYM56Neutral
NZ:AFT54Neutral
NZ:PEB42Neutral
NZ:TRU37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 80Outperform | NZD 29.00B | 61.61 | 22.84% | 1.24% | 15.59% | 23.94% | |
| 60Neutral | NZD 4.53B | 16.71 | 7.99% | 5.69% | 16.36% | 5.52% | |
| 56Neutral | NZD 1.86B | -11.12 | -4.17% | ― | 11.86% | 72.99% | |
| 54Neutral | NZD 481.37M | 32.46 | 14.07% | 0.64% | 22.44% | 23.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 42Neutral | NZD 316.68M | -6.66 | -190.54% | ― | -47.36% | -3.79% | |
| 37Underperform | NZD 8.38M | -2.58 | -75.57% | ― | 42.20% | 23.68% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NZ:FPH | Fisher & Paykel Healthcare Corporation Limited | 49.29 | 12.57 | 34.25% | |
| NZ:EBO | EBOS Group Limited | 21.65 | -5.75 | -20.98% | |
| NZ:PEB | Pacific Edge Limited | 0.26 | 0.07 | 40.88% | |
| NZ:RYM | Ryman Healthcare | 1.83 | -1.06 | -36.66% | |
| NZ:TRU | TruScreen Group Ltd. | 0.01 | -0.01 | -41.18% | |
| NZ:AFT | AFT Pharmaceuticals Ltd. | 4.59 | 0.93 | 25.38% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 05, 2026